비교리스트

 카트 문의
시장보고서
상품코드
1566753

통증 관리 의약품 시장 : 약물 종류별, 적응증별, 통증 유형별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Pain Management Drugs Market By Drug Class , By Indication By Pain Type : Global Opportunity Analysis and Industry Forecast, 2024-2033
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 216 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

통증 관리 의약품 시장

통증 관리 의약품 시장은 2023년 726억 달러로 평가되며, 2024-2033년 연평균 4.2% 성장하여 2033년에는 1,096억 달러에 달할 것으로 예상됩니다.

통증 관리 의약품은 중등도의 불편함에서 심한 통증에 이르기까지 통증을 완화하기 위해 처방되는 약물입니다. 통증 관리 의약품은 오피오이드, 항우울제, 아세트아미노펜과 같은 다양한 약물 계열로 구성됩니다. 이들 약물은 근골격계, 신경병성, 염증성 등 다양한 유형의 통증을 대상으로 합니다. 통증 관리 의약품의 작용 기전은 염증을 억제하고, 신경계의 통증 신호를 억제하며, 통증 인식을 조절하기 위해 뇌의 화학제품을 변화시키는 등 다양합니다.

뇌졸중, 심장병, 제2형 당뇨병, 암과 같은 생활습관병 및 만성질환의 증가가 통증 관리제 시장을 주도하고 있습니다. 또한, 투여 횟수를 줄이는 서방형 제제 등 약물의 제형과 전달 방법의 발전은 환자의 순응도와 치료 효과를 높이기 위해 약물의 수요를 증가시키고 있습니다. 최근에는 나노입자가 표적을 정확하게 찾아내고 저용량으로 장기적인 효능을 제공할 수 있을 것으로 예상됨에 따라 나노 치료의 탐색이 시장에서 활발히 이루어지고 있습니다.

그러나 통증 관리 의약품은 심혈관계 질환, 소화관 출혈, 진정, 신장 손상, 호흡 억제 등 심각한 부작용이 있어 소비량이 제한되어 시장 확대에 걸림돌이 되고 있습니다. 기존 약물의 위험성을 제거하기 위해 부작용이 거의 없는 천연 대체 약물이 검토되고 있습니다. 예를 들어, 미트라기나 스페시오사(Mitragyna spesiosa) 나무에서 추출한 허브 물질인 크라톰(Kratom)은 오피오이드 약품의 대안으로 활용되고 있습니다. 크라톰 의약품은 섬유근육통, 관절염, 신경병성 통증과 같은 만성 통증을 완화하는 데 매우 효과적임이 입증되었습니다.

부문 리뷰

통증 관리 의약품 시장은 약물 종류별, 적응증별, 통증 유형별, 지역별 시장으로 구분됩니다. 약물 종류별로는 비스테로이드성 항염증제, 마취제, 항경련제, 항편두통제, 항우울제, 오피오이드, 비마약성 진통제로 나뉩니다. 적응증별로는 관절통, 신경병증성 통증, 암성 통증, 만성 요통, 수술 후 통증, 편두통, 섬유근육통, 근좌상 및 근긴장, 골절, 급성 맹장염, 기타로 나뉩니다. 통증 유형에 따라 만성 통증과 급성통증으로 나뉩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

약물 종류별로는 오피오이드 부문이 예측 기간 동안 시장을 지배할 것으로 예상됩니다.

적응증별로는 수술 후 통증 부문이 2033년까지 최대 주주가 될 것으로 예상됩니다.

통증 유형별로는 만성 통증 부문이 예측 기간 동안 시장을 주도할 것으로 예상됩니다.

지역별로는 북미가 2033년까지 가장 높은 수익을 올릴 것으로 예상됩니다.

이 보고서는 사용자 정의가 가능합니다.

  • 규제 가이드라인
  • 고객의 관심사에 따른 기업 프로파일 추가
  • 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
  • 기업 개요 확대 목록
  • 과거 시장 데이터
  • 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 소개

제2장 주요 요약

제3장 시장 상황

  • 시장 정의와 범위
  • 주요 조사 결과
    • 주요 투자 기회
    • 주요 성공 전략
  • Porter's Five Forces 분석
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회

제4장 통증 관리 의약품 시장 : 약물 종류별

  • 시장 개요
  • 비스테로이드성 항염증제
  • 마취제
  • 항경련제
  • 항편두통약
  • 항우울제
  • 오피오이드
  • 비마약성 진통제

제5장 통증 관리 의약품 시장 : 적응증별

  • 시장 개요
  • 관절통
  • 신경병증성 통증
  • 암성 통증
  • 만성 요통
  • 수술후 통증
  • 편두통
  • 섬유근육통
  • 근육 염좌/좌상
  • 골절
  • 급성 충수염
  • 기타

제6장 통증 관리 의약품 시장 : 통증 유형별

  • 시장 개요
  • 만성 통증
  • 급성 통증

제7장 통증 관리 의약품 시장 : 지역별

  • 시장 개요
  • 북미
    • 주요 시장 동향과 기회
    • 미국의 통증 관리 의약품 시장
    • 캐나다의 통증 관리 의약품 시장
    • 멕시코의 통증 관리 의약품 시장
  • 유럽
    • 주요 시장 동향과 기회
    • 독일의 통증 관리 의약품 시장
    • 프랑스의 통증 관리 의약품 시장
    • 영국의 통증 관리 의약품 시장
    • 이탈리아의 통증 관리 의약품 시장
    • 스페인의 통증 관리 의약품 시장
    • 기타 유럽의 통증 관리 의약품 시장
  • 아시아태평양
    • 주요 시장 동향과 기회
    • 일본의 통증 관리 의약품 시장
    • 중국의 통증 관리 의약품 시장
    • 인도의 통증 관리 의약품 시장
    • 호주의 통증 관리 의약품 시장
    • 한국의 통증 관리 의약품 시장
    • 기타 아시아태평양의 통증 관리 의약품 시장
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향과 기회
    • 브라질의 통증 관리 의약품 시장
    • 사우디아라비아의 통증 관리 의약품 시장
    • 남아프리카공화국의 통증 관리 의약품 시장
    • 기타 라틴아메리카, 중동 및 아프리카 통증 관리 의약품 시장

제8장 경쟁 상황

  • 소개
  • 주요 성공 전략
  • 주요 10개 기업 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 기업의 포지셔닝(2023년)

제9장 기업 개요

  • Novartis AG
  • Eli Lilly And Company
  • Abbott Laboratories
  • Endo Health Solutions, Inc.
  • Purdue Pharma L.P.
  • Pfizer, Inc.
  • Viatris Inc.
  • Merck And Co. Inc.
  • Johnson And Johnson
  • GlaxoSmithKline Plc
ksm 24.10.15

Pain Management Drugs Market

The pain management drugs market was valued at $72.6 billion in 2023 and is projected to reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033.

A pain management drug is medication prescribed for the alleviation of pain ranging from moderate discomfort to severe distress. The formulation of pain management drugs comprises of different drug class, including opioids, antidepressants or acetaminophen. These medications target diverse pain types, including musculoskeletal, neuropathic, and inflammatory pain. The mechanisms pertaining to the functioning of pain management drug are diverse such as lowering of inflammation, inhibition of pain signals in the nervous system, or alteration of brain chemistry to modulate the perception of pain.

Increase in the prevalence of lifestyle and chronic diseases such as stroke, heart disease, type II diabetes, and cancer is driving the pain management drugs market. In addition, advancements in drug formulations and delivery methods such as extended-release formulations with reduced dosing frequency are boosting the demand for the drugs as they enhance patient compliance & treatment outcomes. In recent times, explorations in nanotherapeutics are trending in the market as nanoparticles are anticipated to possess the capability of precisely identifying the target and offering long-term efficacy in significantly low dosage.

However, the severe side-effects of pain management drugs; including cardiovascular events, gastrointestinal bleeding, sedation, renal impairment, and respiratory depression; limit their consumption, hence presenting challenges for market expansion. To eliminate the hazards of conventional drugs, natural alternatives are being explored as they have potentially minimal to no side-effects. For instance, Kratom, a herbal substance obtained from the Mitragyna speciosa tree, is being utilized as an alternative to opioid drugs. Kratom medications have proved to be highly effective in providing relief from chronic pain conditions such as fibromyalgia & arthritis and neuropathic pain.

Segment Review

The pain management drugs market is segmented into drug class, indication, pain type, and region. On the basis of drug class, the market is divided into NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. As per indication, it is classified into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, acute appendicitis, and others. By pain type, it is bifurcated into chronic pain and acute pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug class, the opioids segment is expected to dominate the market during the forecast period.

As per indication, the postoperative pain segment is predicted to be the highest shareholder by 2033.

By pain type, the chronic pain segment is anticipated to lead the market during the forecast period.

Region wise, North America is projected to be the highest revenue generator by 2033.

Competition Analysis

The major players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Viatris Inc., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Muscle Sprain/Strain
  • Bone Fracture
  • Acute Appendicitis
  • Others

By Pain Type

  • Chronic Pain
  • Acute Pain

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Novartis AG
    • Eli Lilly & Company
    • Abbott Laboratories
    • Endo Health Solutions, Inc.
    • Purdue Pharma L.P.
    • Pfizer, Inc.
    • Viatris Inc.
    • Merck & Co. Inc.
    • Johnson & Johnson
    • GlaxoSmithKline Plc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Class
  • 4.2. NSAIDs
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Anesthetics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Anticonvulsants
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Anti-migraine Agents
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Antidepressants
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country
  • 4.7. Opioids
    • 4.7.1. Key Market Trends, Growth Factors and Opportunities
    • 4.7.2. Market Size and Forecast, By Region
    • 4.7.3. Market Share Analysis, By Country
  • 4.8. Nonnarcotic Analgesics
    • 4.8.1. Key Market Trends, Growth Factors and Opportunities
    • 4.8.2. Market Size and Forecast, By Region
    • 4.8.3. Market Share Analysis, By Country

CHAPTER 5: PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Arthritic Pain
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Neuropathic Pain
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Cancer Pain
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Chronic Back Pain
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Postoperative Pain
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Migraine
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country
  • 5.8. Fibromyalgia
    • 5.8.1. Key Market Trends, Growth Factors and Opportunities
    • 5.8.2. Market Size and Forecast, By Region
    • 5.8.3. Market Share Analysis, By Country
  • 5.9. Muscle Sprain/Strain
    • 5.9.1. Key Market Trends, Growth Factors and Opportunities
    • 5.9.2. Market Size and Forecast, By Region
    • 5.9.3. Market Share Analysis, By Country
  • 5.10. Bone Fracture
    • 5.10.1. Key Market Trends, Growth Factors and Opportunities
    • 5.10.2. Market Size and Forecast, By Region
    • 5.10.3. Market Share Analysis, By Country
  • 5.11. Acute Appendicitis
    • 5.11.1. Key Market Trends, Growth Factors and Opportunities
    • 5.11.2. Market Size and Forecast, By Region
    • 5.11.3. Market Share Analysis, By Country
  • 5.12. Others
    • 5.12.1. Key Market Trends, Growth Factors and Opportunities
    • 5.12.2. Market Size and Forecast, By Region
    • 5.12.3. Market Share Analysis, By Country

CHAPTER 6: PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Pain Type
  • 6.2. Chronic Pain
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Acute Pain
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: PAIN MANAGEMENT DRUGS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Drug Class
    • 7.2.3. Market Size and Forecast, By Indication
    • 7.2.4. Market Size and Forecast, By Pain Type
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Pain Management Drugs Market
      • 7.2.6.1. Market Size and Forecast, By Drug Class
      • 7.2.6.2. Market Size and Forecast, By Indication
      • 7.2.6.3. Market Size and Forecast, By Pain Type
    • 7.2.7. Canada Pain Management Drugs Market
      • 7.2.7.1. Market Size and Forecast, By Drug Class
      • 7.2.7.2. Market Size and Forecast, By Indication
      • 7.2.7.3. Market Size and Forecast, By Pain Type
    • 7.2.8. Mexico Pain Management Drugs Market
      • 7.2.8.1. Market Size and Forecast, By Drug Class
      • 7.2.8.2. Market Size and Forecast, By Indication
      • 7.2.8.3. Market Size and Forecast, By Pain Type
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Drug Class
    • 7.3.3. Market Size and Forecast, By Indication
    • 7.3.4. Market Size and Forecast, By Pain Type
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Pain Management Drugs Market
      • 7.3.6.1. Market Size and Forecast, By Drug Class
      • 7.3.6.2. Market Size and Forecast, By Indication
      • 7.3.6.3. Market Size and Forecast, By Pain Type
    • 7.3.7. France Pain Management Drugs Market
      • 7.3.7.1. Market Size and Forecast, By Drug Class
      • 7.3.7.2. Market Size and Forecast, By Indication
      • 7.3.7.3. Market Size and Forecast, By Pain Type
    • 7.3.8. UK Pain Management Drugs Market
      • 7.3.8.1. Market Size and Forecast, By Drug Class
      • 7.3.8.2. Market Size and Forecast, By Indication
      • 7.3.8.3. Market Size and Forecast, By Pain Type
    • 7.3.9. Italy Pain Management Drugs Market
      • 7.3.9.1. Market Size and Forecast, By Drug Class
      • 7.3.9.2. Market Size and Forecast, By Indication
      • 7.3.9.3. Market Size and Forecast, By Pain Type
    • 7.3.10. Spain Pain Management Drugs Market
      • 7.3.10.1. Market Size and Forecast, By Drug Class
      • 7.3.10.2. Market Size and Forecast, By Indication
      • 7.3.10.3. Market Size and Forecast, By Pain Type
    • 7.3.11. Rest of Europe Pain Management Drugs Market
      • 7.3.11.1. Market Size and Forecast, By Drug Class
      • 7.3.11.2. Market Size and Forecast, By Indication
      • 7.3.11.3. Market Size and Forecast, By Pain Type
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Drug Class
    • 7.4.3. Market Size and Forecast, By Indication
    • 7.4.4. Market Size and Forecast, By Pain Type
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Pain Management Drugs Market
      • 7.4.6.1. Market Size and Forecast, By Drug Class
      • 7.4.6.2. Market Size and Forecast, By Indication
      • 7.4.6.3. Market Size and Forecast, By Pain Type
    • 7.4.7. China Pain Management Drugs Market
      • 7.4.7.1. Market Size and Forecast, By Drug Class
      • 7.4.7.2. Market Size and Forecast, By Indication
      • 7.4.7.3. Market Size and Forecast, By Pain Type
    • 7.4.8. India Pain Management Drugs Market
      • 7.4.8.1. Market Size and Forecast, By Drug Class
      • 7.4.8.2. Market Size and Forecast, By Indication
      • 7.4.8.3. Market Size and Forecast, By Pain Type
    • 7.4.9. Australia Pain Management Drugs Market
      • 7.4.9.1. Market Size and Forecast, By Drug Class
      • 7.4.9.2. Market Size and Forecast, By Indication
      • 7.4.9.3. Market Size and Forecast, By Pain Type
    • 7.4.10. South Korea Pain Management Drugs Market
      • 7.4.10.1. Market Size and Forecast, By Drug Class
      • 7.4.10.2. Market Size and Forecast, By Indication
      • 7.4.10.3. Market Size and Forecast, By Pain Type
    • 7.4.11. Rest of Asia-Pacific Pain Management Drugs Market
      • 7.4.11.1. Market Size and Forecast, By Drug Class
      • 7.4.11.2. Market Size and Forecast, By Indication
      • 7.4.11.3. Market Size and Forecast, By Pain Type
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Drug Class
    • 7.5.3. Market Size and Forecast, By Indication
    • 7.5.4. Market Size and Forecast, By Pain Type
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Pain Management Drugs Market
      • 7.5.6.1. Market Size and Forecast, By Drug Class
      • 7.5.6.2. Market Size and Forecast, By Indication
      • 7.5.6.3. Market Size and Forecast, By Pain Type
    • 7.5.7. Saudi Arabia Pain Management Drugs Market
      • 7.5.7.1. Market Size and Forecast, By Drug Class
      • 7.5.7.2. Market Size and Forecast, By Indication
      • 7.5.7.3. Market Size and Forecast, By Pain Type
    • 7.5.8. South Africa Pain Management Drugs Market
      • 7.5.8.1. Market Size and Forecast, By Drug Class
      • 7.5.8.2. Market Size and Forecast, By Indication
      • 7.5.8.3. Market Size and Forecast, By Pain Type
    • 7.5.9. Rest of LAMEA Pain Management Drugs Market
      • 7.5.9.1. Market Size and Forecast, By Drug Class
      • 7.5.9.2. Market Size and Forecast, By Indication
      • 7.5.9.3. Market Size and Forecast, By Pain Type

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novartis AG
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Eli Lilly And Company
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Abbott Laboratories
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Endo Health Solutions, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Purdue Pharma L.P.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Pfizer, Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Viatris Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Merck And Co. Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Johnson And Johnson
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. GlaxoSmithKline Plc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제